China National Accord Medicines Corporation Ltd.

SZSE:000028 Stock Report

Market Cap: CN¥13.0b

China National Accord Medicines Future Growth

Future criteria checks 3/6

China National Accord Medicines is forecast to grow earnings and revenue by 32.1% and 5.7% per annum respectively. EPS is expected to grow by 32.2% per annum. Return on equity is forecast to be 7.3% in 3 years.

Key information

32.1%

Earnings growth rate

32.16%

EPS growth rate

Healthcare earnings growth20.6%
Revenue growth rate5.7%
Future return on equity7.35%
Analyst coverage

Good

Last updated02 May 2025

Recent future growth updates

China National Accord Medicines Corporation Ltd. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Oct 30
China National Accord Medicines Corporation Ltd. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Recent updates

China National Accord Medicines' (SZSE:000028) Returns On Capital Not Reflecting Well On The Business

Mar 14
China National Accord Medicines' (SZSE:000028) Returns On Capital Not Reflecting Well On The Business

Here's Why China National Accord Medicines (SZSE:000028) Can Manage Its Debt Responsibly

Jan 22
Here's Why China National Accord Medicines (SZSE:000028) Can Manage Its Debt Responsibly

Lacklustre Performance Is Driving China National Accord Medicines Corporation Ltd.'s (SZSE:000028) Low P/E

Nov 18
Lacklustre Performance Is Driving China National Accord Medicines Corporation Ltd.'s (SZSE:000028) Low P/E

China National Accord Medicines Corporation Ltd. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Oct 30
China National Accord Medicines Corporation Ltd. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

China National Accord Medicines (SZSE:000028) Seems To Use Debt Quite Sensibly

Oct 10
China National Accord Medicines (SZSE:000028) Seems To Use Debt Quite Sensibly

China National Accord Medicines Corporation Ltd.'s (SZSE:000028) Low P/E No Reason For Excitement

Aug 13
China National Accord Medicines Corporation Ltd.'s (SZSE:000028) Low P/E No Reason For Excitement

Estimating The Intrinsic Value Of China National Accord Medicines Corporation Ltd. (SZSE:000028)

Jul 12
Estimating The Intrinsic Value Of China National Accord Medicines Corporation Ltd. (SZSE:000028)

Is China National Accord Medicines (SZSE:000028) A Risky Investment?

Jun 12
Is China National Accord Medicines (SZSE:000028) A Risky Investment?

Improved Earnings Required Before China National Accord Medicines Corporation Ltd. (SZSE:000028) Shares Find Their Feet

May 12
Improved Earnings Required Before China National Accord Medicines Corporation Ltd. (SZSE:000028) Shares Find Their Feet

Analysts Are Updating Their China National Accord Medicines Corporation Ltd. (SZSE:000028) Estimates After Its Full-Year Results

Apr 10
Analysts Are Updating Their China National Accord Medicines Corporation Ltd. (SZSE:000028) Estimates After Its Full-Year Results

China National Accord Medicines Corporation Ltd. (SZSE:000028) Shares Could Be 28% Below Their Intrinsic Value Estimate

Mar 15
China National Accord Medicines Corporation Ltd. (SZSE:000028) Shares Could Be 28% Below Their Intrinsic Value Estimate

China National Accord Medicines (SZSE:000028) Has A Rock Solid Balance Sheet

Feb 29
China National Accord Medicines (SZSE:000028) Has A Rock Solid Balance Sheet

Earnings and Revenue Growth Forecasts

SZSE:000028 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202784,2241,531N/A2,0422
12/31/202683,1611,434N/A1,9507
12/31/202578,0411,209N/A1,4273
3/31/202573,5825821,8132,088N/A
12/31/202474,3786422,9893,271N/A
9/30/202475,3581,4752,4522,753N/A
6/30/202474,8761,5122,0732,380N/A
3/31/202475,8811,6261,7692,093N/A
12/31/202375,4771,5992,6152,937N/A
9/30/202375,4121,6291,6561,968N/A
6/30/202375,7021,6432,6743,005N/A
3/31/202374,9791,5972,6722,988N/A
12/31/202273,4431,4872,2382,560N/A
9/30/202272,7651,3101,9312,293N/A
6/30/202271,3241,2691,0981,467N/A
3/31/202269,4591,2601,3601,744N/A
12/31/202168,3581,3361,2851,655N/A
9/30/202166,9791,478592939N/A
6/30/202165,6431,5009701,294N/A
3/31/202162,8751,4821,5791,884N/A
12/31/202059,6491,4021,2091,503N/A
9/30/202056,2441,3062,6632,937N/A
6/30/202054,3581,2622,0582,312N/A
3/31/202053,5391,2171,8652,113N/A
12/31/201952,7871,2681,7612,013N/A
9/30/201950,7791,2431,5461,817N/A
6/30/201947,9431,2181,9652,236N/A
3/31/201944,9371,2171,1401,399N/A
12/31/201843,1221,211N/A1,323N/A
9/30/201841,7511,182N/A1,338N/A
6/30/201841,5171,143N/A1,282N/A
3/31/201841,2981,078N/A923N/A
12/31/201741,2631,058N/A1,285N/A
9/30/201741,4181,080N/A1,155N/A
6/30/201741,2111,084N/A871N/A
3/31/201741,1591,205N/A959N/A
12/31/201641,2481,187N/A1,472N/A
9/30/201649,2491,263N/A1,878N/A
6/30/201645,5681,199N/A1,839N/A
3/31/201641,870984N/A1,286N/A
12/31/201537,819928N/A1,457N/A
9/30/201525,740721N/A201N/A
6/30/201525,155693N/A136N/A
3/31/201524,683682N/A-189N/A
12/31/201423,954652N/A-797N/A
9/30/201423,418629N/A-369N/A
6/30/201422,680607N/A-258N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 000028's forecast earnings growth (32.1% per year) is above the savings rate (2.7%).

Earnings vs Market: 000028's earnings (32.1% per year) are forecast to grow faster than the CN market (23.4% per year).

High Growth Earnings: 000028's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 000028's revenue (5.7% per year) is forecast to grow slower than the CN market (12.3% per year).

High Growth Revenue: 000028's revenue (5.7% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 000028's Return on Equity is forecast to be low in 3 years time (7.3%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/23 12:30
End of Day Share Price 2025/05/23 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

China National Accord Medicines Corporation Ltd. is covered by 24 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Lei TianAJ Securities Co., Ltd
Shuchang LiuChangjiang Securities Co. LTD.
Yanyin ZhuChina International Capital Corporation Limited